Esperion Therapeutics
Lipid-lowering therapeutics
Delisted (Nasdaq: ESPR): taken private by ARCHIMED, merger completed 2026-07-13 · United States
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Bempedoic acid(Nexletol) | Approved | ATP citrate lyaseSmall molecule | Atherosclerotic Cardiovascular Disease |
Bempedoic acid/ezetimibe(Nexlizet) | Approved | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (14)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $80M | $9.0M | $156M | $25M | report ↗ |
View 13 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $87M | $14M | $92M | $31M | report ↗ |
| 2025-Q2 | $82M | $7.2M | $86M | $13M | report ↗ |
| 2025-Q1 | $65M | $13M | $115M | $40M | report ↗ |
| 2024-Q3 | $52M | $10M | $145M | $30M | report ↗ |
| 2024-Q2 | $74M | $11M | $189M | $62M | report ↗ |
| 2024-Q1 | $138M | $13M | $227M | — | report ↗ |
| 2023-Q3 | $34M | $15M | $115M | $41M | report ↗ |
| 2023-Q2 | $26M | $22M | $138M | $50M | report ↗ |
| 2023-Q1 | $24M | $31M | $145M | $62M | report ↗ |
| 2022-Q3 | $19M | $29M | $209M | $55M | report ↗ |
| 2022-Q2 | $19M | $32M | $173M | $66M | report ↗ |
| 2022-Q1 | $19M | $24M | $200M | $57M | report ↗ |
| 2021-Q3 | $14M | $25M | $154M | $69M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $403M | $48M | $168M | $5.7M | report ↗ |
Esperion Therapeutics reported revenue of $403.14M, up 21.3% YoY, R&D spend of $47.85M, up 3.5% YoY, cash and equivalents of $167.85M, and a net loss of $22.68M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text